文献速递血栓与止血

维生素K拮抗剂治疗门诊静脉血栓栓塞患者显著出血的预测

Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients.
PubMed 文献 · Br J Haematol · 2020-01-29

本研究基于英国临床实践研究数据链,开发并验证了一个预测维生素K拮抗剂(VKA)治疗静脉血栓栓塞(VTE)后90天内显著出血的风险评分。

要点

  • 该评分有助于识别门诊VTE患者中VKA相关显著出血高风险者,尤其大出血。
  • 独立预测因素包括活动性癌症、创伤/手术、男性、痴呆、肝病、贫血等。

核心结论

  • 开发的风险评分可识别门诊VTE患者中VKA相关显著出血风险较高者,尤其大出血事件。

主要发现

  • 显著出血的独立预测因素包括活动性癌症、创伤/手术、男性、痴呆、肝病、贫血、出血史、脑血管病、肾病、慢性肺病、以肺栓塞起病的VTE及年龄>75岁。
  • 该评分C统计量高于应用于研究人群的其他风险方案。

关键数值与推荐

  • 显著出血事件定义为VKA启动后90天内发生的大出血和需住院的临床相关非大出血(CRNMB-H)。
  • 风险评分基于子风险比开发,经交叉验证,以C统计量表达。

临床怎么用

  • 该评分可用于门诊VTE患者启动VKA治疗时评估显著出血风险,辅助风险/获益评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bleeding is the most concerning complication associated with anticoagulant therapy but poorly characterized and important for risk/benefit assessment. We developed a risk stratification score to predict vitamin K antagonist (VKA)-associated bleeding in venous thromboembolism (VTE) using the UK Clinical Practice Research Datalink. Significant bleeding events in outpatients consisted of major bleeding and clinically relevant non-major bleeding requiring hospitalisation (CRNMB-H) within 90 days of VKA initiation. A scoring scheme for predicting bleeding was developed from subhazard ratios, validated using cross-validation and expressed by the C-statistic. The study cohort consisted of 10,010 patients with first VTE receiving initial VKA treatment, mean age 62·2 years. Between 2008 and 2016, 167 significant bleeding events were recorded (1·7%), i.e. incidence rate was 7·4/100 person-years. Independent predictors for community-acquired significant bleeding included active cancer, trauma/surgical procedure, male gender, dementia, liver disease, anaemia, history of bleeding, cerebrovascular, renal and chronic pulmonary disease, VTE presenting as pulmonary embolism and age over 75. The overall C-statistic was 0·68 (95% CI, 0·60-0·76), 0·75 (0·60-0·88) for major bleeding and 0·65 (0·55-0·75) for CRNMB-H, and higher than in other risk schemes applied to our study population. The developed risk score may identify patients having a significant bleeding risk, in particular major bleeding events, in outpatients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Martinez C, Katholing A, Wallenhorst C, et al. Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients. Br J Haematol. 2020. PMID: 31997309. doi:10.1111/bjh.16383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。